- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - BOSTON & COPENHAGEN, ...
Researchers identified several antibodies to the nucleocapsid protein from a convalescent COVID-19 patient. Tests found some can inhibit complement hyperactivation and could potentially lead to new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback